- Title: Subtitle
- A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group (GOG) study
- Creators
- D.P. Bender - University of IowaM. Sill - Gynecologic Oncology GroupH. Lankes - Gynecologic Oncology GroupC.J. Darus - Maine Medical CenterJ. Delmore - Wichita State UniversityJ. Rotmensch - Rush University Medical CenterH.J. Gray - University of Washington Medical CenterR.S. Mannel - University of Oklahoma Health Sciences CenterJ.M. Schilder - Indiana UniversityK.K. Leslie - University of IowaH.D. Reyes - University of Iowa Hospitals and ClinicsM. Hunter - University of MissouriC.K. McCourt - Washington University in St. LouisM. Samuelson - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Gynecologic oncology, Vol.138, pp.2-2
- DOI
- 10.1016/j.ygyno.2015.04.018
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 05/2015
- Academic Unit
- Pathology; Obstetrics and Gynecology
- Record Identifier
- 9984316895302771
Abstract
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group (GOG) study
Gynecologic oncology, Vol.138, pp.2-2
05/2015
DOI: 10.1016/j.ygyno.2015.04.018
Details
Metrics
18 Record Views